OrthoPediatrics

OrthoPediatrics has announced the full commercial launch of its 3P hip plating system after a limited rollout with more than 350 surgical implantations in the US. The first product in the Pediatric Plating Platform includes angle-stable proximal femur plates and beam-screw constructs in configurations for infants, children and adolescents to treat trauma and deformities. The company views the market launch as a milestone for the Trauma & Deformity business and plans to introduce additional systems within the product family. » Więcej na de.investing.com

OrthoPediatrics reported a record quarter with revenue of $70.5m (+15% year‑over‑year), beating consensus expectations. The company raised its full-year revenue guidance to $265–269m and recorded adjusted EBITDA of $6.8m. Strong growth came from trauma, deformity correction and specialty braces, while the scoliosis segment declined. Management expects positive free cash flow in the second half and sees further growth drivers from new products and EU approvals. » Więcej na de.investing.com

OrthoPediatrics has launched the TRAXIO Complete - Weight System, a halo-extension traction system for controlled, weight-dependent realignment of the spine in infants, children and adolescents. The mechanical system uses weights and a pulley and complements halo-extension therapy in clinical settings in combination with a separately cleared halo ring-and-pin system. The product expands the company’s specialty-bracing portfolio, which includes over 85 pediatric orthopedics products; OrthoPediatrics most recently reported $236.35 million in revenue with 15.45% growth and a gross margin of 73%. » Więcej na de.investing.com

OrthoPediatrics agreed to amend its existing credit line and establish a delayed draw term loan facility of up to $20 million, callable in tranches of $10 million no later than June 30, 2027. The interest rate is SOFR (floor 3.25%) plus 6.50% p.a., with a 1.00% payment-in-kind option and interest-only payments until maturity on August 5, 2029. The company reports a current ratio of 5.55, 15% revenue growth last year and is not required to draw on the facility; fees and exit provisions align with the original loan agreement. » Więcej na de.investing.com

OrthoPediatrics presented its growth strategy at the Citizens Life Sciences Conference and is targeting free cash flow break-even by 2026. The company is expanding pediatric-specific solutions (from 17 to 87 systems) and expects OPSB business to grow more than 20% annually. For 2026, it forecasts EBITDA of about $25 million while planning to scale back investments. OrthoPediatrics is accelerating hospital expansion near children’s hospitals and sees market opportunities from competitors withdrawing products due to EU MDR compliance. » Więcej na de.investing.com